Kymera Therapeutics (KYMR) Stock Price, Quote, News & History | Benzinga

Kymera Therapeutics Inc (KYMR) Stock Price, Quote, News & History

KYMRNASDAQ

Trade with Public

Trade with Public

$123.30

-4.01-3.15%

Last update: Aug 20, 12:41 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$124.98

Close

-

Volume / Avg.

192.63K / 838.76K

Day Range

$122.33 - $125.45

52 Wk Range

39.84 - 130.05

Market Cap

$10.25B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

15.44%

Days to Cover

18.07

Recent Kymera Therapeutics, Inc. News

This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.

Avi Kapoor

Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program

Kymera Therapeutics shares surged after completing KT-621 Phase 2b enrollment early, accelerating data timing and Phase 3 plans.

Vandana Singh

Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High

U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, while consumer discretionary fell 1.1%. Core PCE rose 3.4% in May.

Avi Kapoor

Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday

Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.

Avi Kapoor

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC, MLTX, FRVO, and SMCI.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-236.76M

Investing Cash Flow (TTM)

-752.49M

Financing Cash Flow (TTM)

777.92M

Free Cash Flow (TTM)

-237.96M

Capital Expenditure (TTM)

-1.19M

Net Change in Cash (TTM)

-211.34M

Analyst Trends and Forecast

1

May

5

Jun

2

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$9.97B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

113.02

PB Ratio (TTM)

7.01

Earnings Yield % (TTM)

-2.55%

Earnings Yield % (FWD)

-3.12%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$18.15

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$1.70M

Total Cash

$124.48M

Debt to Equity

0.05

Issuance of Debt (TTM)

-$1.70M

Repayment of Debt (TTM)

-$1.70M

Key Statistics

Open

$124.98

Close

-

Volume / Avg.

192.63K / 838.76K

Day Range

$122.33 - $125.45

52 Wk Range

39.84 - 130.05

Market Cap

$10.25B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

15.44%

Days to Cover

18.07

About

Sector

Health Care

Industry

Biotechnology

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. I...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Kymera Therapeutics (KYMR) stock?

A

You can purchase shares of Kymera Therapeutics (NASDAQ:KYMR) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Kymera Therapeutics (KYMR) competitors?

A

Other companies in Kymera Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Kymera Therapeutics (KYMR) stock?

A

Kymera Therapeutics has a consensus price target of $107.67.

Q

What is the current price for Kymera Therapeutics (KYMR)?

A

The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $123.3 last updated August 20, 2026 at 12:41 PM EDT.

Q

Does Kymera Therapeutics (KYMR) pay a dividend?

A

There are no upcoming dividends for Kymera Therapeutics.

Q

When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?

A

Kymera Therapeutics does not have any upcoming earnings scheduled.

Q

Is Kymera Therapeutics (KYMR) going to split?

A

There is no upcoming split for Kymera Therapeutics.

Q

What sector and industry does Kymera Therapeutics (KYMR) operate in?

A

Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.